The Book Alzheimer S Disease

In this second edition Dr. Newport, a neonatal practitioner, continues the story of Steve's progress and provides the most recent research on such topics as possible causes of Alzheimer's due to the herpes simplex virus and nitrosamine substances and how infection, inflammation and genetic makeup may affect an individual's response to fatty acid therapy.

Nearly 44 million people have Alzheimer’s or related dementia worldwide, according to the Alzheimer’s Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy covers recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer’s and other forms of dementia. First, readers are introduced to cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to other symptoms, and the quality of life for those with Alzheimer’s disease. In addition, the book discusses recent studies on memory dysfunction in advanced-stage Alzheimer’s disease, in comparison to early-stage, including a chapter on the underlying factors in the transition from mild cognitive impairment to Alzheimer’s diagnosis. Following this section, the book presents recent studies on the role of different cortical and subcortical structures in the development of various symptoms in Alzheimer’s disease, as well as different neural biomarkers underlying the development and treatment of the disease. In the last section of the book, therapeutic aspects of Alzheimer’s disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, are reviewed. The book aids readers in understanding the advances in research and care, making it a prime tool for all clinicians, psychologists, researchers, neurologists, and caregivers of dementia patients. Reviews recent developments of cognitive and clinical studies Covers factors underlying the transition from mild cognitive impairment to Alzheimer’s disease Discusses different neural biomarkers underlying the development and treatment of Alzheimer’s disease Provides a comparison of the effectiveness of various types of treatments

This book provides a practically focused resource on the methodologies available for diagnosing and treating Alzheimer’s disease. The number of individuals affected by the disease continues to grow and as such there is an ever-increasing need for clear easy-to-digest guidance on how to appropriately diagnose and treat these patients. Within this work, chapters provide concise informative details of what this form of dementia is, how it can be diagnosed, managed and prevented making it ideal for those with limited experience in dealing with these patients. Information is provided on how to use a variety of the latest relevant techniques including mental state examinations, functional assessments, special investigations and the available drug treatments. Alzheimer’s Disease: Diagnosis & Treatment Guide is a concise clinical guide detailing how to diagnose and treat these patients. It’s easy-to-follow ideal for use by front-line physicians and trainees, who have no previous experience of diagnosing and treating this disease. The assessment component of the book is based on the WHO Mental Health Gap Action Plan (mhGAP) Dementia Intervention Guide for non-specialized settings.

An authority on Alzheimer's disease offers a history of past failures and a roadmap that points us in a new direction in our journey to a cure. For decades, some of our best and brightest medical scientists have dedicated themselves to finding a cure for Alzheimer's disease. What happened? Where is the cure? The biggest breakthroughs occurred twenty-five years ago, with little progress since. In How Not to Study a Disease, neurobiologist Karl Herrup explains why the Alzheimer's discoveries of the 1990s didn't bear fruit and maps a direction for future research. Herrup describes the research, explains what's taking so long, and offers an approach for resetting future research. Herrup offers a unique insider's perspective, describing the red flags that science ignored in the rush to find a cure. He is unsparing in calling out the stubbornness, greed, and bad advice that has hamstrung the field, but his final message is a largely optimistic one. Herrup presents a new and sweeping vision of the field that includes a redefinition of the disease and a fresh conceptualization of aging and dementia that asks us to imagine the brain as a series of interconnected "neighborhoods." He calls for changes in virtually every aspect of the Alzheimer's disease research effort, from the drug development process, to the mechanisms of support for basic research, to the often-overlooked role of the scientific media, and more. With How Not to Study a Disease, Herrup provides a roadmap that points us in a new direction in our journey to a cure for Alzheimer's.

The instant New York Times and Wall Street Journal bestseller A groundbreaking plan to prevent and reverse Alzheimer’s Disease that fundamentally changes how we understand cognitive decline. Everyone knows someone who has survived cancer, but until now no one knows anyone who has survived Alzheimer's Disease. In this paradigm shifting book, Dale Bredesen, MD, offers real hope to anyone looking to prevent and even reverse Alzheimer's Disease and cognitive decline. Revealing that AD is not one condition, as it is currently treated, but three, The End of Alzheimer’s outlines 36 metabolic factors (micronutrients, hormone levels, sleep) that can trigger "downsizing" in the brain. The protocol shows us how to rebalance these factors using lifestyle modifications like taking B12, eliminating gluten, or improving oral hygiene. The results are impressive. Of the first ten patients on the protocol, nine displayed significant improvement with 3-6 months; since then the protocol has yielded similar results with hundreds more. Now, The End of Alzheimer’s brings new hope to a broad audience of patients, caregivers, physicians, and treatment centers with a fascinating look inside the science and a complete step-by-step plan that fundamentally changes how we treat and even think about AD.

The 36-Hour Day is the definitive dementia care guide.

A guide to more successful communication for the millions of Americans caring for someone with dementia: “Offers a fresh approach and hope.”—NPR Revolutionizing the way we perceive and live with Alzheimer’s, Joanne Koenig Coste offers a practical approach to the emotional well-being of both patients and caregivers that emphasizes relating to patients in their own reality. Her accessible and comprehensive method, which she calls habilitation, works to enhance communication between care partners and patients and has proven successful with thousands of people living with dementia. Learning to Speak Alzheimer’s also offers hundreds of practical tips, including how to: · cope with the diagnosis and adjust to the disease’s progression · help the patient talk about the illness · face the issue of driving · make meals and bath times as pleasant as possible · adjust room design for the patient’s comfort · deal with wandering, paranoia, and aggression “A fine addition to Alzheimer's and caregiving collections.”—Library Journal (starred review) “Promises to transform not only the lives of patients but those of care providers…This book is a gift.”—Sue Levkoff, coauthor of Aging Well